Randomized Study to Evaluate the Effect of an Investigational Product on Weight Loss and Body Composition
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of IHBG-10 on Weight Loss and Body Composition
1 other identifier
interventional
10
1 country
1
Brief Summary
This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight loss, and changes in body composition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2 obesity
Started Feb 2011
Shorter than P25 for phase_2 obesity
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 6, 2011
CompletedFirst Posted
Study publicly available on registry
January 10, 2011
CompletedStudy Start
First participant enrolled
February 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2011
CompletedOctober 6, 2011
January 1, 2011
5 months
January 6, 2011
October 4, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Weight
12 weeks
Secondary Outcomes (1)
Body composition
12 weeks
Study Arms (2)
Study Group
EXPERIMENTALSubjects will take 500 mg of the investigational product 15 minutes prior to the 3 main meals of the day.
Control Group
PLACEBO COMPARATORSubjects will take a placebo 15 minutes prior to the three main meals of the day.
Interventions
Eligibility Criteria
You may qualify if:
- Age 18 and older
- Body mass index of 30 or greater
- Agree to keep diet, exercise and all current health habits stable during participation in the study
You may not qualify if:
- Women who are pregnant, breastfeeding or planning to become pregnant
- Prior bariatric surgery
- Use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month
- Obesity as a result of a clinically diagnosed endocrine problem
- Currently taking an anti-psychotic medication
- History of peptic ulcer disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Avera Research Institute
Sioux Falls, South Dakota, 57105, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Edward Zawada, MD
Avera McKennan Hospital & University Health Center
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 6, 2011
First Posted
January 10, 2011
Study Start
February 1, 2011
Primary Completion
July 1, 2011
Study Completion
July 1, 2011
Last Updated
October 6, 2011
Record last verified: 2011-01